Targeting TGF-β in prostate cancer: Therapeutic possibilities during tumor progression

Elisabeth Jones, H. Pu, Natasha Kyprianou

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background : TGF-β regulates prostate growth by inhibiting epithelial cell proliferation and inducing apoptosis through eliciting a dynamic signaling pathway. In metastatic prostate cancer, however, TGF-β serves as a tumor promoter. TGF-β engages Smad-dependent and Smad-independent mechanisms to exert its action. During prostate tumorigenesis, prostate cells exhibit loss or mutation of TGF-β transmembrane receptors. Increased production of TGF-β causes immunosuppression, extracellular matrix degrada tion, epithelia to mesenchymal transition and angiogenesis that promotes tumor cell invasion and metastasis. Objective : The molecular basis for effective therapeutic targeting of TGF-β must be directed towards the double-edge-sword nature of the cytokine: Inhibiting the TGF-β tumor promoter capabilities in advanced metastatic prostate cancer, although retaining the growthinhibitory abilities exhibited in early stages of prostate tumorigenesis. Results/conclusion : The current understanding of the therapeutic possibilities of targeting TGF-β signaling during prostate tumor progression is built on preclinical studies. Studies targeting TGF-β signaling pathway for the treatment of several human malignancies include the use of neutralizing antibodies, antisense oligonucelotides and small molecule inhibitors of kinase activity of the receptor complex. This review focuses on exploiting the therapeutic potential of targeting TGF-β signaling in the context of its contribution to prostate cancer initiation and progression to metastasis.

Original languageEnglish
Pages (from-to)227-234
Number of pages8
JournalExpert Opinion on Therapeutic Targets
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Tumors
Prostate
Prostatic Neoplasms
Carcinogens
Neoplasms
Carcinogenesis
Neoplasm Metastasis
Cell proliferation
Therapeutics
Neutralizing Antibodies
Phosphotransferases
Immunosuppression
Cells
Extracellular Matrix
Apoptosis
Cytokines
Epithelium
Molecules
Epithelial Cells
Cell Proliferation

Keywords

  • Apoptosis signaling
  • Prostate cancer
  • Smad-targeting
  • TGF-β

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Targeting TGF-β in prostate cancer : Therapeutic possibilities during tumor progression. / Jones, Elisabeth; Pu, H.; Kyprianou, Natasha.

In: Expert Opinion on Therapeutic Targets, Vol. 13, No. 2, 02.2009, p. 227-234.

Research output: Contribution to journalArticle

@article{b6cb370cc7e24f169cfaa4f3748a9596,
title = "Targeting TGF-β in prostate cancer: Therapeutic possibilities during tumor progression",
abstract = "Background : TGF-β regulates prostate growth by inhibiting epithelial cell proliferation and inducing apoptosis through eliciting a dynamic signaling pathway. In metastatic prostate cancer, however, TGF-β serves as a tumor promoter. TGF-β engages Smad-dependent and Smad-independent mechanisms to exert its action. During prostate tumorigenesis, prostate cells exhibit loss or mutation of TGF-β transmembrane receptors. Increased production of TGF-β causes immunosuppression, extracellular matrix degrada tion, epithelia to mesenchymal transition and angiogenesis that promotes tumor cell invasion and metastasis. Objective : The molecular basis for effective therapeutic targeting of TGF-β must be directed towards the double-edge-sword nature of the cytokine: Inhibiting the TGF-β tumor promoter capabilities in advanced metastatic prostate cancer, although retaining the growthinhibitory abilities exhibited in early stages of prostate tumorigenesis. Results/conclusion : The current understanding of the therapeutic possibilities of targeting TGF-β signaling during prostate tumor progression is built on preclinical studies. Studies targeting TGF-β signaling pathway for the treatment of several human malignancies include the use of neutralizing antibodies, antisense oligonucelotides and small molecule inhibitors of kinase activity of the receptor complex. This review focuses on exploiting the therapeutic potential of targeting TGF-β signaling in the context of its contribution to prostate cancer initiation and progression to metastasis.",
keywords = "Apoptosis signaling, Prostate cancer, Smad-targeting, TGF-β",
author = "Elisabeth Jones and H. Pu and Natasha Kyprianou",
year = "2009",
month = "2",
doi = "10.1517/14728220802705696",
language = "English",
volume = "13",
pages = "227--234",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Targeting TGF-β in prostate cancer

T2 - Therapeutic possibilities during tumor progression

AU - Jones, Elisabeth

AU - Pu, H.

AU - Kyprianou, Natasha

PY - 2009/2

Y1 - 2009/2

N2 - Background : TGF-β regulates prostate growth by inhibiting epithelial cell proliferation and inducing apoptosis through eliciting a dynamic signaling pathway. In metastatic prostate cancer, however, TGF-β serves as a tumor promoter. TGF-β engages Smad-dependent and Smad-independent mechanisms to exert its action. During prostate tumorigenesis, prostate cells exhibit loss or mutation of TGF-β transmembrane receptors. Increased production of TGF-β causes immunosuppression, extracellular matrix degrada tion, epithelia to mesenchymal transition and angiogenesis that promotes tumor cell invasion and metastasis. Objective : The molecular basis for effective therapeutic targeting of TGF-β must be directed towards the double-edge-sword nature of the cytokine: Inhibiting the TGF-β tumor promoter capabilities in advanced metastatic prostate cancer, although retaining the growthinhibitory abilities exhibited in early stages of prostate tumorigenesis. Results/conclusion : The current understanding of the therapeutic possibilities of targeting TGF-β signaling during prostate tumor progression is built on preclinical studies. Studies targeting TGF-β signaling pathway for the treatment of several human malignancies include the use of neutralizing antibodies, antisense oligonucelotides and small molecule inhibitors of kinase activity of the receptor complex. This review focuses on exploiting the therapeutic potential of targeting TGF-β signaling in the context of its contribution to prostate cancer initiation and progression to metastasis.

AB - Background : TGF-β regulates prostate growth by inhibiting epithelial cell proliferation and inducing apoptosis through eliciting a dynamic signaling pathway. In metastatic prostate cancer, however, TGF-β serves as a tumor promoter. TGF-β engages Smad-dependent and Smad-independent mechanisms to exert its action. During prostate tumorigenesis, prostate cells exhibit loss or mutation of TGF-β transmembrane receptors. Increased production of TGF-β causes immunosuppression, extracellular matrix degrada tion, epithelia to mesenchymal transition and angiogenesis that promotes tumor cell invasion and metastasis. Objective : The molecular basis for effective therapeutic targeting of TGF-β must be directed towards the double-edge-sword nature of the cytokine: Inhibiting the TGF-β tumor promoter capabilities in advanced metastatic prostate cancer, although retaining the growthinhibitory abilities exhibited in early stages of prostate tumorigenesis. Results/conclusion : The current understanding of the therapeutic possibilities of targeting TGF-β signaling during prostate tumor progression is built on preclinical studies. Studies targeting TGF-β signaling pathway for the treatment of several human malignancies include the use of neutralizing antibodies, antisense oligonucelotides and small molecule inhibitors of kinase activity of the receptor complex. This review focuses on exploiting the therapeutic potential of targeting TGF-β signaling in the context of its contribution to prostate cancer initiation and progression to metastasis.

KW - Apoptosis signaling

KW - Prostate cancer

KW - Smad-targeting

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=64349120177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64349120177&partnerID=8YFLogxK

U2 - 10.1517/14728220802705696

DO - 10.1517/14728220802705696

M3 - Article

C2 - 19236240

AN - SCOPUS:64349120177

VL - 13

SP - 227

EP - 234

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 2

ER -